智能手机居家尿白蛋白肌酐比值检测对白蛋白尿筛查与管理的影响
这项非随机临床试验在大型区域健康系统中比较了智能手机居家UACR检测与常规护理对白蛋白尿筛查完成率的影响。干预组高血压亚组和糖尿病亚组的UACR完成率均为53%,显著高于对照组的13%和30%;居家检测结果异常者更可能获得随访和RAAS抑制剂处方。
要点
- 智能手机居家UACR检测可显著提高高血压和糖尿病患者的白蛋白尿筛查完成率。
- 居家检测异常者(UACR≥30 mg/g)更可能接受随访和RAAS抑制剂治疗。
- 患者门户非使用者中居家检测完成率较低,需关注数字鸿沟。
核心结论
- 智能手机居家白蛋白尿检测可有效提高高风险人群的白蛋白尿筛查完成率,并促进异常者的临床管理。
研究设计与样本
- 非随机临床试验,干预组为3,998名随机选取的成人(50%高血压无糖尿病,50%糖尿病),对照组为3,998名倾向性评分匹配的常规护理者。
主要发现
- 高血压亚组UACR完成率干预组53% vs 对照组13%,糖尿病亚组53% vs 30%。
- 居家检测UACR异常(≥30 mg/g)在高血压亚组为38%(330/872),糖尿病亚组为45%(306/682)。
- 居家检测异常者比正常者更可能进行初级保健和肾内科随访,并新处方RAAS抑制剂。
- 检测完成率在不同年龄、性别、种族和民族亚组中一致,但患者门户非使用者较低。
关键数值与推荐
- 主要结局为项目开始后100天内完成UACR检测(实验室或居家)。
- UACR异常定义为≥30 mg/g。
临床怎么用
- 对高血压或糖尿病患者,可考虑采用智能手机居家UACR检测以提高白蛋白尿筛查率。
- 居家检测异常结果应促使随访和启动RAAS抑制剂等肾脏保护治疗。
- 需关注患者门户非使用者,采取措施确保其也能完成居家检测。
局限性
- 尽管干预组随机分配,但研究整体为非随机设计。
- 干预仅限于1个大型农村健康系统。
- 未评估GLP-1受体激动剂在CKD中的使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Early detection of albuminuria can enable administration of therapeutic interventions that improve clinical outcomes in patients at elevated risk for chronic kidney disease (CKD). We investigated the impact of smartphone-enabled home urinary albumin-creatinine ratio (UACR) testing on albuminuria screening and clinical management of these patients. STUDY DESIGN: Nonrandomized clinical trial. SETTING & PARTICIPANTS: Active intervention group comprised 3,998 randomly selected adults (50% with hypertension but no diabetes; 50% with diabetes) receiving primary care at a large, regional health system compared with 3,998 propensity score-matched controls who were receiving usual care. INTERVENTIONS: Minuteful Kidney, a smartphone-enabled home UACR test kit cleared by the US Food and Drug Administration. OUTCOME: The primary outcome was completion of UACR testing (either laboratory-based or home testing) within 100 days of program start. ANALYTICAL APPROACH: Covariate balance between matched groups was evaluated using the standardized mean difference (SMD). Outcomes were compared between the 2 matched groups using McNemar's test. RESULTS: Overall, completion of any UACR test was higher in the intervention program than in the control group for the hypertension subgroup (53% vs 13%) and the diabetes subgroup (53% vs 30%). Greater UACR testing with Minuteful Kidney was consistent across age, sex, race, and ethnicity subgroups, though lower in nonusers of the patient portal. The Minuteful Kidney UACR results were abnormal (≥30 mg/g) in 38% (330 of 872) in the hypertension subgroup and in 45% (306 of 682) in the diabetes subgroup. Among the Minuteful Kidney-tested individuals, those with abnormal UACR were more likely to have follow-up primary care and nephrology visits and new prescriptions of renin-angiotensin-aldosterone system inhibitors than those with normal UACR. LIMITATIONS: Despite random assignment to intervention, this was not a randomized study; intervention was limited to 1 large rural health system; use of glucagon-like peptide-1 receptor agonists in CKD was not assessed. CONCLUSIONS: A convenient smartphone-enabled home albuminuria test is effective in increasing albuminuria screening among high-risk individuals. PLAIN LANGUAGE SUMMARY: This study evaluated whether a smartphone-enabled home albuminuria test could improve chronic kidney disease (CKD) screening among adults with hypertension or diabetes. We found that home testing increased albuminuria test completion 2.5-fold in the intervention group compared with the control group (53% vs 21%). The impact was larger in the hypertension-only subgroup (53% vs 13%) than in the diabetes subgroup (53% vs 30%). Among those tested at home, 38% (hypertension subgroup) and 45% (diabetes subgroup) had abnormal albuminuria levels. These individuals were more likely to have follow-up care and new prescriptions for certain kidney-protective medications. These findings support the use of home albuminuria testing as an effective strategy to increase screening and early intervention for kidney disease in high-risk populations.
引用
- Zafar W, Hu Y, Brubaker L, et al. Impact of Smartphone-Enabled Home Urinary Albumin-Creatinine Ratio Testing on Albuminuria Screening and Management. Am J Kidney Dis. 2025. PMID: 41360254. doi:10.1053/j.ajkd.2025.09.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。